drugset
drugset / Trial / NCT02518607

Safety, Blood Levels and Effects of MGB-BP-3

NCT02518607 ↗

Phase 1 Completed 40 enrolled MGB Biopharma Limited Analytical Services International Limited · collabCambridge Regulatory Services · collabHammersmith Medicines Research · collabInnovate UK · collabPhases Clinical Research Limited · collabSynlab Services · collabViapath · collab
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study is to assess the safety and tolerability aspects of oral MGB-BP-3, a treatment for Clostridium difficile infections.

Timeline

Start
2015-07
Primary completion
2015-11
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Subject MGB-BP-3 Small molecule 250 mg Oral
Subject MGB-BP-3 Small molecule 500 mg Oral
Subject MGB-BP-3 Small molecule 750 mg Oral
Subject MGB-BP-3 Small molecule 1000 mg Oral
Subject MGB-BP-3 Small molecule 1250 mg Oral
Subject MGB-BP-3 Small molecule 1500 mg Oral
Subject MGB-BP-3 Small molecule 2000 mg Oral

Indications

No indication recorded.